Curadev is a private, clinical-stage biotechnology company founded in 2015, advancing a pipeline of novel small molecule drugs. Its lead asset, CRD3874-SI, is a first-in-class allosteric STING agonist in Phase 1 trials via a collaboration with Memorial Sloan Kettering Cancer Center. The company also has preclinical programs targeting STING antagonism, TNIK, and CLK/DYRK, supported by a leadership team with deep, long-standing relationships in drug discovery.
Target-centric drug discovery integrating innovative screening schemes with classical medicinal chemistry and pharmacology, supplemented by translational academic collaborations for early target identification.
Funding History
2
Total raised:$40M
Series B$25MNovartis Venture Fund
Series A$15MSR One
Opportunities
Positive Phase 1 data for its first-in-class STING agonist could attract significant partnership or acquisition interest in the competitive immuno-oncology space.
Its diverse pipeline targeting large markets like NASH, osteoarthritis, and neuroinflammation provides multiple shots on goal and opportunities for out-licensing.
Risk Factors
The company faces high clinical risk with its novel STING agonist and will require substantial additional capital to advance its pipeline, leading to potential dilution.
It also operates in intensely competitive therapeutic areas against larger, better-funded entities.
Competitive Landscape
Curadev competes in the crowded STING modulator space against numerous biopharma companies (e.g., Novartis, GSK, Aduro). Its neuroinflammation and fibrosis programs also face competition from both large pharma and biotech firms. Differentiation relies on novel chemotypes and specific mechanisms, such as allosteric STING agonism.
